FDG-PET improves the management of patients with suspected recurrence of colorectal cancer

被引:33
作者
Simó, M [1 ]
Lomeña, F [1 ]
Setoain, J [1 ]
Pérez, G [1 ]
Castellucci, P [1 ]
Costansa, JM [1 ]
Setoain-Quinquer, J [1 ]
Doménech-Torné, F [1 ]
Carrió, I [1 ]
机构
[1] CETIR PET Ctr, Barcelona 08950, Spain
关键词
colorectal cancer; recurrence; FDG-PET; management; treatment planning;
D O I
10.1097/00006231-200210000-00007
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study aims to assess the influence of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) detection of recurrent disease on the management of patients with colorectal cancer and suspected recurrence. One hundred and twenty patients with suspected recurrence were studied with FDG-PET. Fifty-eight patients were referred for FDG-PET because of the elevation of serum tumour markers. Thirty-one patients were referred because of inconclusive results of conventional imaging modalities. Twenty-five patients had known recurrence and were referred for pre-surgical assessment. Six patients were referred because of abdominal pain. A major management change was considered when, as a consequence of FDG-PET results, medical treatment was changed to surgical, or surgical to medical or to no treatment. A minor management change was considered when changes were made within a treatment modality. Of the 58 patients with elevated serum carcinoembryonic antigen (CEA), FDG-PET detected recurrence and led to a major management change in 34 (58%). Eighteen underwent curative surgery and 16 were treated with systemic therapy. Of the 31 patients evaluated because of inconclusive results of conventional imaging modalities, FDG-PET was positive for recurrence in 24 and negative in seven. A major management change took place in 14 patients (45%). Of the 25 patients evaluated to rule out other sites of disease before surgery, FDG-PET did not show any other site of recurrence in 13 (52%) and showed more lesions in the remaining patients. Major management change took place in eight patients (32%). Overall, in the 120 patients studied, FDG-PET resulted in major management changes in 58 (48%), minor changes in four (3%) and no change in 54 (45%). It can be concluded that FDG-PET has a significant impact on the management of patients with suspected recurrence of colorectal cancer. FDG-PET detection of recurrence frequently allows curative surgical intervention. The early identification of distant metastases may also facilitate the implementation of systemic treatment. ((C) 2002 Lippincott Williams Wilkins).
引用
收藏
页码:975 / 982
页数:8
相关论文
共 42 条
[1]   Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings [J].
Abdel-Nabi, H ;
Doerr, RJ ;
Lamonica, DM ;
Cronin, VR ;
Galantowicz, P ;
Carbone, GM ;
Spaulding, MB .
RADIOLOGY, 1998, 206 (03) :755-760
[2]  
Akhurst T, 1999, SEMIN ONCOL, V26, P577
[3]   Positron emission tomography and colorectal cancer [J].
Arulampalam, THA ;
Costa, DC ;
Loizidou, M ;
Visvikis, D ;
Ell, PJ ;
Taylor, I .
BRITISH JOURNAL OF SURGERY, 2001, 88 (02) :176-189
[4]   CARCINOMA OF THE COLON - DETECTION AND PREOPERATIVE STAGING BY CT [J].
BALTHAZAR, EJ ;
MEGIBOW, AJ ;
HULNICK, D ;
NAIDICH, DP .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1988, 150 (02) :301-306
[5]   METASTASECTOMY [J].
BARR, LC ;
SKENE, AI ;
THOMAS, JM .
BRITISH JOURNAL OF SURGERY, 1992, 79 (12) :1268-1274
[6]   Staging of colorectal cancer [J].
Berlin, JW ;
Gore, RM ;
Yaghmai, V ;
Newmark, GM ;
Miller, FH .
SEMINARS IN ROENTGENOLOGY, 2000, 35 (04) :370-384
[7]  
COHEN AM, 1993, PRINCIPLES PRACTICE, P929
[8]  
Delbeke D, 1997, J NUCL MED, V38, P1196
[9]   A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps [J].
Fenlon, HM ;
Nunes, DP ;
Schroy, PC ;
Barish, MA ;
Clarke, PD ;
Ferrucci, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (20) :1496-1503
[10]   Positron emission tomography in the clinical evaluation of metastatic cancer [J].
Fischman, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :691-696